GARRETT L WALSH to Radiopharmaceuticals
This is a "connection" page, showing publications GARRETT L WALSH has written about Radiopharmaceuticals.
Connection Strength
0.263
-
Limitations of 18F-2-deoxy-D-glucose positron emission tomography in N1 detection in patients with pathologic stage II-N1 and implications for management. Ann Thorac Surg. 2015 Feb; 99(2):414-20.
Score: 0.085
-
2-Fluoro-2-deoxy-D-glucose positron emission tomography imaging is predictive of pathologic response and survival after preoperative chemoradiation in patients with esophageal carcinoma. Cancer. 2004 Oct 15; 101(8):1776-85.
Score: 0.042
-
Clinical Significance of [18F] Fluoro-2-Deoxy-d-Glucose/Computed Tomographic Avid Hilar Lymph Nodes in Esophageal Carcinoma Patients. Ann Thorac Surg. 2022 10; 114(4):1183-1188.
Score: 0.034
-
Preoperative Maximum Standardized Uptake Value Associated With Recurrence Risk in Early Lung Cancer. Ann Thorac Surg. 2022 06; 113(6):1835-1844.
Score: 0.034
-
18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer. Cancer Immunol Immunother. 2020 Aug; 69(8):1519-1534.
Score: 0.031
-
Imaging of non-small cell lung cancer of the superior sulcus: part 1: anatomy, clinical manifestations, and management. Radiographics. 2008 Mar-Apr; 28(2):551-60; quiz 620.
Score: 0.013
-
Imaging of non-small cell lung cancer of the superior sulcus: part 2: initial staging and assessment of resectability and therapeutic response. Radiographics. 2008 Mar-Apr; 28(2):561-72.
Score: 0.013
-
Utility of PET, CT, and EUS to identify pathologic responders in esophageal cancer. Ann Thorac Surg. 2004 Oct; 78(4):1152-60; discussion 1152-60.
Score: 0.010